Sionna Therapeutics (SION) said late Thursday it has priced an initial public offering of about 10.6 million shares at $18 per share for expected gross proceeds of $191 million.
The cystic fibrosis-focused pharmaceutical firm said its shares are scheduled to begin Nasdaq trading Friday under the ticker symbol "SION."
Sionna has also granted underwriters a 30-day option to purchase up to about 1.6 million additional shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.